Compare GEL & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GEL | MLTX |
|---|---|---|
| Founded | 1996 | 2021 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | 1996 | 2020 |
| Metric | GEL | MLTX |
|---|---|---|
| Price | $14.20 | $18.95 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 12 |
| Target Price | $19.50 | ★ $27.50 |
| AVG Volume (30 Days) | 432.0K | ★ 1.3M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.19% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,912,770,000.00 | N/A |
| Revenue This Year | $12.12 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 43.60 | N/A |
| 52 Week Low | $13.75 | $5.95 |
| 52 Week High | $18.64 | $62.75 |
| Indicator | GEL | MLTX |
|---|---|---|
| Relative Strength Index (RSI) | 38.18 | 49.10 |
| Support Level | $13.75 | $15.54 |
| Resistance Level | $16.38 | $19.24 |
| Average True Range (ATR) | 0.53 | 1.12 |
| MACD | 0.02 | -0.11 |
| Stochastic Oscillator | 23.75 | 22.78 |
Genesis Energy LP focuses on the midstream segment of the crude oil and natural gas industry. It offers various services to crude oil and natural gas producers, and industrial and commercial enterprises. The company's reportable segments are: Offshore pipeline transportation, Marine transportation, and Onshore transportation and services. Maximum revenue is generated from the Offshore pipeline transportation segment, which includes the transportation and processing of crude oil and natural gas in the Gulf of America. The Marine transportation segment provides waterborne transportation of petroleum products and crude oil throughout North America; and the Onshore transportation and services segment deals with crude oil logistics, sour gas processing, and sells sulfur byproducts.
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.